National Heart, Lung, and Blood Institute
Overview
The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. The NHLBI stimulates basic discoveries about the causes of disease, enables the translation of basic discoveries into clinical practice, fosters training and mentoring of emerging scientists and physicians, and communicates research advances to the public.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Makani Science | May 2025 | Grant | Co-investor |
| SafeBeat Rx | Sep 2024 | Grant | Lead |
| Nanite, Inc. | Aug 2023 | Grant | Lead |
| KeViRx, Inc. | Oct 2021 | Grant | Co-investor |
| Centerline Biomedical | Apr 2020 | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is National Heart, Lung, and Blood Institute based?
National Heart, Lung, and Blood Institute is headquartered in Bethesda, Maryland, United States.
When was National Heart, Lung, and Blood Institute founded?
National Heart, Lung, and Blood Institute was founded in 1948.
How many portfolio companies does National Heart, Lung, and Blood Institute have?
National Heart, Lung, and Blood Institute has 26 portfolio companies in Caplight's dataset.
What are some companies in National Heart, Lung, and Blood Institute's portfolio?
Portfolio companies visible on Caplight include Makani Science, SafeBeat Rx, Nanite, Inc., KeViRx, Inc., Centerline Biomedical.
What was National Heart, Lung, and Blood Institute's most recent investment shown here?
National Heart, Lung, and Blood Institute's most recent investment in this portfolio sample was in Makani Science in 2025.
What sectors does National Heart, Lung, and Blood Institute focus on?
National Heart, Lung, and Blood Institute focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Enterprise Software, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Enterprise Software, Frontier & Industrial Tech.
What company stages does National Heart, Lung, and Blood Institute focus on?
National Heart, Lung, and Blood Institute typically invests at the MultiStage stage.
What is National Heart, Lung, and Blood Institute's AUM?
National Heart, Lung, and Blood Institute's assets under management are estimated between $1.0B and $10.0B.